+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 50Years - 80Years
All Genders
ID07168993

Non-invasive Flow Cytometry-Based Diagnostic Test Using Sputum Samples to Detect Early Lung Cancer in High-Risk Patients with Lung Nodules

Led by bioAffinity Technologies Inc. · Updated on 2026-10-16

2063

Participants Needed

11

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the FlowPath Lung Test, a non-invasive diagnostic tool using flow cytometry on sputum samples, to detect early-stage lung cancer in high-risk individuals. Participants have existing lung nodules between 6 and less than 30 millimeters in diameter, identified by low-dose computed tomography LDCT. The study focuses on assessing how sensitive and specific this test is for identifying lung cancer among those at elevated risk. Participants provide sputum samples for diagnostic testing with the FlowPath Lung Test within 12 weeks of their baseline CT scan. The study involves standard medical treatment and follow-up as per the institutions usual care. The lung nodules considered are either new, increasing, or stable for up to six months, and in cases of multiple nodules, the most suspicious nodule is selected for analysis. During the study, researchers will monitor participants for up to 24 months following the baseline sputum sample to measure the tests ability to detect early-stage lung cancer. Participants medical information related to their standard care follow-up will be collected. The primary outcome is the detection of early-stage lung cancer using the FlowPath Lung Test over this follow-up period, with ongoing standard medical care continuing throughout the study.

CONDITIONS

Brief Title

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

Research Team

X

Xavier T Reveles, MS, CG(ASCP)

S

Stacy K Stanek

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here